Author Affiliations: Neuro-Ophthalmology Unit, Mason Eye Institute, University of Missouri–Columbia.
Glaucoma is a progressive optic neuropathy with features similar to nonarteritic anterior ischemic optic neuropathy (NAION), the most common optic neuropathy causing acute vision loss. Glaucoma has an annual incidence rate of 240 per capita, while NAION has an annual incidence of 2.3 per capita among individuals older than 50 years.1,2 Early diabetes mellitus (DM)—defined as an absence of clinically visible diabetic retinopathy—may be associated with upregulation and downregulation of intraocular interferon, interleukins, and other cytokines promoting neuroprotection.3 The initial Ocular Hypertension Treatment Study report documented a protective effect of early DM in glaucoma development, but reanalysis showed no effect.4,5 Studies have shown DM to be a risk factor for NAION, but it is possible that early DM could have neuroprotective effects in NAION. Hayreh and Zimmerman6 had documented less severe visual field loss for diabetic patients with NAION. However, 11% of their participants had juvenile diabetes, 36% had diabetic retinopathy, and the investigators had used manual kinetic perimetry. To discern the role of early DM in NAION, we have studied patients aged 50 years or older without diabetic retinopathy using automated static perimetry.
We reviewed the records of all patients with NAION evaluated by the neuro-ophthalmology service between October 1990 and August 2009, after obtaining institutional review board approval. Criteria for NAION were similar to those used in past studies.2 Patients were excluded if they had significant cataract, presumed toxic causes of NAION such as amiodarone hydrochloride or erectile dysfunction drug use, perioperative NAION, diabetic retinopathy, temporal arteritis, or other disorders that could cause the vision loss. A standardized comprehensive medical history and comprehensive neuro-ophthalmologic examination were obtained for all patients, including best-corrected visual acuity, Humphrey automated perimetry program 24-2 or 30-2 Swedish interactive thresholding algorithm fast results, and dilated ophthalmoscopy.
Patients were classified as having DM with or without hypertension or not having DM with or without hypertension. Diabetes was identified if the patient had been diagnosed by the primary care physician as having DM or if the patient had been prescribed oral hypoglycemic medications or insulin prior to NAION. Patients with hypertension had been prescribed antihypertensive medications. Usable visual fields had less than 33% fixation loss, false-negative errors, and false-positive errors. Statistical analyses were performed with SAS version 9 statistical software (SAS Institute, Inc, Cary, North Carolina). We compared categorical variables such as sex with χ2 test, ordinal variables such as age with Wilcoxon rank sum test, and logMAR visual acuity and mean deviation on visual field with 2-sample t test and analyses of variance and covariance.
A total of 206 patients (53 with DM [43 having hypertension] and 153 without DM [73 having hypertension]) who were aged 50 years or older (mean age, 65.1 years; male, 122 [59%]) qualified for the study. There were 176 usable visual fields (45 with DM and 131 without DM). There was no significant difference in logMAR visual acuity (P = .77) for DM (mean [SD], 0.81 [0.71]) and no DM (mean [SD], 0.84 [0.79]) or when accounting for the presence or absence of hypertension (P = .10) (Table). There was no significant difference in visual field mean deviation (P = .52) for DM (mean [SD], −18.5 [9.8] dB) and no DM (mean [SD], −17.5 [9.1] dB) or when accounting for the presence or absence of hypertension (P = .34). There was no trend for better (or worse) visual field for DM compared with no DM (Cochran-Armitage test, P = .79).
Among patients with NAION, those with early DM had a similar degree of visual acuity and visual field loss compared with those without DM. There was no trend for patients with early DM to have a better or worse visual field after NAION compared with patients without DM. Early DM is neither protective nor harmful in NAION with respect to the severity of vision loss.
Correspondence: Dr Johnson, Neuro-Ophthalmology Unit, Mason Eye Institute, University of Missouri–Columbia, 1 Hospital Dr, Columbia, MO 65212 (firstname.lastname@example.org).
Financial Disclosure: None reported.
Funding/Support: This work was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc, New York, New York, to the Department of Ophthalmology, University of Missouri–Columbia.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
Example 1: Diabetes and Target Blood Pressure
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.